Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 10/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16238548 | 1.00 | LMNA (0.55) | LMNANPSR1L3MBTL1NPC1USP30 | |
| SCHEMBL9892918 | 0.93 | LMNA (0.50) | LMNANPSR1L3MBTL1NPC1USP30 | |
| SCHEMBL13257821 | 0.79 | CNR2 (0.67) | LMNANPSR1L3MBTL1NPC1USP30 | |
| SCHEMBL16238263 | 0.79 | CNR2 (0.67) | LMNANPSR1L3MBTL1NPC1USP30 | |
| SCHEMBL16238371 | 0.79 | CNR2 (0.56) | LMNANPSR1L3MBTL1NPC1USP30 | |
| SCHEMBL16238373 | 0.79 | CNR2 (0.56) | LMNANPSR1L3MBTL1NPC1USP30 | |
| SCHEMBL16238476 | 0.77 | LMNA (0.53) | LMNANPSR1L3MBTL1NPC1USP30 | |
| SCHEMBL16238478 | 0.77 | LMNA (0.53) | LMNANPSR1L3MBTL1NPC1USP30 | |
| SCHEMBL9107269 | 0.77 | L3MBTL1 (0.61) | LMNANPSR1L3MBTL1NPC1USP30 | |
| SCHEMBL9107258 | 0.77 | L3MBTL1 (0.61) | LMNANPSR1L3MBTL1NPC1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | LMNA 4475/4885NPSR1 72/4885L3MBTL1 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.